University of Washington logo

University of Washington

The University of Washington is a public research university in Seattle operating in higher education, research, and computer science; it...

Facts

HQ
University of Washington
Sectors
Higher Education, Research, Healthcare, Arts
Founded
1861
Registered name
University of Washington Seattle business license
Stage
Public

University of Washington Spinout Aquagga Develops Technology to Destroy PFAS 'Forever Chemicals' with No Toxic Byproducts

Aquagga, a Seattle-based cleantech startup founded by University of Washington and Alaska researchers, develops a high-temperature, high-pressure system to completely destroy PFAS 'forever chemicals' in water and soil with no toxic byproducts. The company aims to address EPA concerns about PFAS contamination by providing scalable destruction technology for environmental remediation.

Techstars CEO Maelle Gavet Highlights Economic Downturn Challenges and Startup Support Role Amid $2.5B Raised by Accelerated Firms

Maelle Gavet, CEO of Techstars, warns of a significant market reset in the tech industry due to an economic downturn but highlights Techstars’ role in helping startups build resilient businesses and secure funding. Since launching in 2006, Techstars has accelerated nearly 3,000 startups, with its Seattle program producing over 130 companies that have raised $2.5 billion collectively.

Pacific Northwest Life Sciences Update: Talus Bioscience Raises $9.75M, Kineta Merges with Yumanity, UW’s David Baker Launches Charm Therapeutics

Recent Pacific Northwest life sciences news includes Talus Bioscience raising $9.75 million, Kineta going public via merger with Yumanity, and UW's David Baker launching Charm Therapeutics. Key partnerships involve TwinStrand and Singular Genomics developing rare gene variant tests, and Umoja Biopharma partnering with TreeFrog Therapeutics for stem cell therapies.

David Baker Launches London Biotech Charm Therapeutics with $50M Series A to Advance Deep Learning Drug Discovery

David Baker, leader of the University of Washington Institute for Protein Design, co-founded London-based Charm Therapeutics, which uses deep learning to discover new small molecule therapeutics, and recently secured $50 million in Series A funding. The company's DragonFold platform predicts protein-small molecule interactions to aid drug discovery in cancer and other diseases.

Five Finalists for 2022 GeekWire Health Innovation of the Year Include A-Alpha Bio and UW Institute for Protein Design

The 2022 GeekWire Health Innovation of the Year finalists include A-Alpha Bio, Parse Biosciences, Tasso, Truveta, and the University of Washington’s Institute for Protein Design, highlighting advances in computational health approaches. Winners will be announced on May 12 at the GeekWire Awards, with community voting open until April 22.

Discovery Health Grew from 8 to 300 Employees Under CEO Ann Jarris by Leading COVID-19 Testing and Vaccinations in Pacific Northwest Maritime Industry

Discovery Health, led by CEO Ann Jarris, experienced significant growth during the COVID-19 pandemic by overseeing testing and vaccinations for maritime, agriculture, and airport workers in the Pacific Northwest. Starting with just eight employees and limited resources, the Seattle-based health startup expanded to a team of nearly 300, becoming a key partner in pandemic response efforts.

Andreessen Horowitz, Madrona and other tech VCs ramp up bets on AI-driven biotech startups as founders from software enter life sciences

Tech venture capital firms like Andreessen Horowitz and Seattle’s Madrona Venture Group are increasingly investing in life-science startups that use AI, machine learning and data science to speed drug discovery and development. Investors are following founders who transitioned from software to biotech—such as Sujal Patel of Nautilus and Terry Myerson of Truveta—seeing reduced perceived risk and new opportunity at this intersection.

Parse Biosciences raises $41.5M to scale Evercode single-cell RNA sequencing kits that profile up to 1M cells

Parse Biosciences, a Seattle startup co-founded by CEO Alex Rosenberg and CTO Charles Roco, raised $41.5 million to expand its single-cell RNA sequencing kits and software, which scale to profile up to one million cells using standard lab equipment. The company, launched from University of Washington research, now has more than 300 customers and emphasizes ease of use versus competitors requiring specialized hardware.

Pack Ventures launches Seattle syndicate to back UW-linked startups, pledges 10% of future profits to University of Washington

Pack Ventures, a new early-stage Seattle VC, will invest $100K–$200K checks in startups tied to the University of Washington and has already backed five companies including Jeeva Wireless, Talus.bio and Monod Bio; the firm will return 10% of individual future profits to UW. The syndicate includes more than 35 founding investors from the Seattle VC and entrepreneur community and will target AI, robotics, computational biology, enterprise software and other high-growth areas.

Seattle tech — including Amazon, Microsoft and startups like Convoy — poised to profit as pandemic-driven supply chain chaos accelerates digital logistics transformation

Persistent COVID-19–related supply chain disruptions have created demand for digital tools, presenting an opportunity for Seattle-area tech firms and startups—alongside Amazon and Microsoft—to provide IoT, cloud, and machine-learning solutions for trucking and logistics. Industry leaders say the pandemic accelerated digital transformation in trucking and may push broader adoption of sensors, edge devices and analytics to reduce delays and visibility gaps.

Seashell raises $6M seed; Khosla, Kindred, Mark Cuban, Vlad Tenev and Coinbase Ventures back Seattle fintech offering up to 10% yields

Seashell, a 15-person Seattle fintech founded by Daryl Hok, raised $6 million in a seed round led by Khosla Ventures and Kindred Ventures with investors including Mark Cuban, Robinhood CEO Vlad Tenev and Coinbase Ventures; the startup offers up to 10% interest by investing user cash in gold and dollar-pegged digital assets but is not FDIC-insured and carries loss risk.

ZeroAvia opens R&D center at Everett’s Paine Field; $5.5M refit and $350K Washington grant support hydrogen-electric powertrain work

ZeroAvia is opening an R&D center at Everett’s Paine Field near Seattle to develop hydrogen-electric aircraft powertrains, with plans to begin customer rollouts in 2024 and potentially build a North American manufacturing hub there. The Paine Field site converts warehouse space into offices and labs, received a $350,000 Washington grant, and will employ 20–30 people initially while ZeroAvia pursues larger-scale manufacturing and powertrains for bigger aircraft.

  • Oren Etzioni
    Oren Etzioni Executive, Former CEO, Founder and Emeritus Professor, Former Professor, Former Leader of TrueMedia
  • Avi Geiger Lecturer, Affiliate Assistant Professor, Electrical and Computer Engineering
  • Babak Parviz
    Babak Parviz Professor

Online